Clinical trial · Interventional
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04250155CI-TRIAL-00116761completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atezolizumab | Drug | Atezolizumab | ALIAS |
| XmAb24306 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Phase 1a Dose Escalation
- description
- Participants will receive XmAb24306 until study treatment discontinuation or study termination.
- interventionNames
- Drug: XmAb24306
- type
- EXPERIMENTAL
- label
- Phase 1a Dose Expansion
- description
- Participants will receive XmAb24306 until study treatment discontinuation or study termination.
- interventionNames
- Drug: XmAb24306
- type
- EXPERIMENTAL
- label
- Phase 1b Dose Escalation
- description
- Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key General Inclusion Criteria * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy \>/= 12 weeks * Adequate hematologic and end-organ function * For participants receiving therapeutic anticoagulation: stable anticoagulant regimen * Negative serum pregnancy test for women of childbearing potential * Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Availability of representative tumor specimens Key General Exclusion Criteria * Pregnant or breastfeeding, or intending to become pregnant during the study * Significant cardiovascular disease * Current treatment with medications that prolong the QT interval * Known clinically significant liver disease * Poorly controlled Type 2 diabetes mellitus * Symptomatic, untreated, or actively progressing CNS metastases * History of leptomeningeal disease * History of malignancy other than disease under study within 3 years prior to screening * Active or history of autoimmune disease or immune deficiency * Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus infection * Positive for HIV infection * Prior allogeneic stem cell or solid organ transplantation
References
Publications (0)
Data not yet available
No reference posted for this study.